IDH1 and glioblastoma: In conclusion, we showed the promising activity of TFDC-based immunotherapy in IDH-WT GBM and the association of low HLA-A expression and the absence of CCDC88A, KRT4, TACC2, and TONSL mutations in tumor cells of patients showing better prognosis.